Oncotelic receives BARDA contract for long Covid-19 therapy development
Oncotelic has received a contract from BARDA to develop OT-101 to treat the long-term effects of respiratory distress after Covid-19 infection.
Stay updated with breaking news from Monitoring Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Oncotelic has received a contract from BARDA to develop OT-101 to treat the long-term effects of respiratory distress after Covid-19 infection.
Some 7.3% of all pharmaceutical industry cloud roles were advertised in Bengaluru (India) in the three months ending July.
The second edition of the Rare Disease Spotlight series investigates the trends in orphan drug designations across therapy areas over almost 40 years.
AnGes signed an agreement for marketing and supply of Eiger Biopharmaceuticals’ Zokinvy for progeria and processing-deficient PL in Japan.
The global Covid death toll has passed the grim milestone of 6 million, with a figure of 6,007,367 according to Johns Hopkins University.